GeNeuro SA — Biomedical Watch V2

Traitements2programmes

Essais2liés

Publications1liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
GNbAC1 Monoclonal AntibodyThe humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis. The study assesses the long-term safety of GNbAC1 in patients with RRMS and the long-term efficacy of GNbAC1 in terms of MRI outcomes, relapse rate, disability and disease progression.	SEP	Phase 2	Ralentissement de la progression	Bulgaria, Croatia, Czechia, Estonia, Germany, Hungary, Italy, Poland, …	À vérifier
GNbAC1 Monoclonal AntibodyThe humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis. The study assesses the long-term safety of GNbAC1 in patients with RRMS and the long-term efficacy of GNbAC1 in terms of MRI outcomes, relapse rate, disability and disease progression.	SEP	Phase 2	Ralentissement de la progression	Bulgaria, Croatia, Czechia, Estonia, Germany, Hungary, Italy, Poland, Russia, Serbia, Spain, Ukraine	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
GNbAC1 Monoclonal Antibody	SEP	Phase 2	NCT03239860	ANGEL-MS — Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis	TERMINATED
GNbAC1	SEP	Phase 2	NCT02782858	CHANGE-MS — Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS	COMPLETED

Publications

1

Molécule	Indication / population	Titre	Journal	Date
GNbAC1 Monoclonal Antibody		HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab.	International journal of molecular sciences